+19.7%
EXC vs MRNA
+27.9%
-8.2%
-18.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | +0.7% | -1.5% | -0.7% |
| 7D | -1.6% | -8.2% | +6.6% | -1.7% |
| 30D | -2.4% | +125.6% | -127.9% | -1.7% |
| 3M | -4.0% | +197.1% | -201.0% | -2.8% |
| 6M | -9.8% | +148.5% | -158.3% | -8.9% |
| YTD | +2.3% | +363.3% | -361.0% | +4.1% |
| 1Y | +3.8% | +462.0% | -458.2% | +6.1% |
| All | +19.7% | +27.9% | -8.2% | +22.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling